Compare CMTV & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMTV | CGEN |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | Israel |
| Employees | 134 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.5M | 270.4M |
| IPO Year | N/A | 2001 |
| Metric | CMTV | CGEN |
|---|---|---|
| Price | $38.08 | $2.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 13.5K | ★ 577.7K |
| Earning Date | N/A | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.53 | $1.30 |
| 52 Week High | $42.92 | $3.24 |
| Indicator | CMTV | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 53.25 |
| Support Level | $37.29 | $1.46 |
| Resistance Level | $42.86 | $3.14 |
| Average True Range (ATR) | 1.65 | 0.18 |
| MACD | -0.15 | -0.03 |
| Stochastic Oscillator | 49.96 | 54.37 |
Community Bancorp Inc is a holding company that provides a complete line of personal and business banking services with personal services and solutions. The company mainly offers Business banking, Commercial real estate lending, residential real estate lending, Retail credit, Municipal and Institutional Banking, and Retail Banking. The company's primary lending products are commercial, real estate, municipal, and consumer loans. The bank offers a complete line of personal and business products and services, along with offerings for non-profit organizations, municipalities, and local governments. The Firm also engages in lending activity outside the area of its branch network, through loan production offices in Burlington, Vermont, and Lebanon, New Hampshire.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.